Quanterix (NASDAQ:QTRX) Announces Earnings Results

Key Points

• Quanterix beat earnings expectations for the quarter, posting earnings of ($0.39) per share versus the expected ($0.51), while revenue came in at $35.9 million, slightly below analyst estimates.
• The company is stepping up its Alzheimer’s diagnostics push, including new hiring, expanded lab infrastructure, a Tempus AI partnership, and a goal of pursuing FDA clearance for LucentAD Complete in the second half of 2026.
• Management said it has achieved $85 million in annualized Akoya cost synergies and ended the quarter with $102.6 million in cash and no debt, while still guiding for full-year 2026 revenue of $169 million to $174 million.

Quanterix (NASDAQ:QTRX - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.12, Zacks reports. Quanterix had a negative return on equity of 23.55% and a negative net margin of 71.86%.The business had revenue of $35.90 million for the quarter, compared to analysts' expectations of $36.84 million.

Here are the key takeaways from Quanterix's conference call:

• Quanterix is increasing investment in its Alzheimer's diagnostics business, hiring a new diagnostics leader, expanding lab infrastructure, pursuing FDA clearance for LucentAD Complete in H2 2026, and announcing a partnership with Tempus AI to integrate ordering into select EHRs.
• The company reported $36.4 million in Q1 revenue (reported +20% YoY but organic revenue declined 21%), with instrumentation sales softer than expected, 16 Simoa and 11 spatial placements, and pharma revenue down ~33% while academia represented ~65% of Q1 sales.
• Management says it has delivered the $85 million of annualized Akoya cost synergies, maintained >50% non-GAAP gross margin, narrowed adjusted EBITDA loss to $9.8 million, and ended the quarter with $102.6 million in cash and no debt while targeting cash-flow breakeven in the second half of 2026.
• Leadership is shifting from integration to growth and has launched commercial effectiveness initiatives—adding lead-generation reps, market development leaders, leveraging Thermo Fisher distribution, and prioritizing an HD‑X upgrade (with an IVD filing planned in 2027) and Simoa1 early-access feedback to drive second-half revenue.
• The company changed its accounting classification for shipping and handling into cost of goods sold (affecting GAAP gross margin presentation but not non-GAAP margins) and reiterated full‑year 2026 revenue guidance of $169 million–$174 million.

Quanterix Stock Performance

Shares of QTRX traded up $0.08 during midday trading on Friday, hitting $2.83. 2,359,120 shares of the stock were exchanged, compared to its average volume of 854,835. Quanterix has a 52-week low of $2.56 and a 52-week high of $8.77. The stock has a fifty day simple moving average of $4.11 and a 200 day simple moving average of $5.60. The firm has a market cap of $133.19 million, a P/E ratio of -1.20 and a beta of 1.15.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. TD Cowen reduced their target price on shares of Quanterix from $7.00 to $4.00 and set a "hold" rating on the stock in a research note on Thursday. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. Canaccord Genuity Group lowered their price objective on Quanterix from $8.00 to $4.00 and set a "hold" rating for the company in a research report on Monday, April 20th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Quanterix in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus price target of $4.00.

Hedge Funds Weigh In On Quanterix

A number of hedge funds and other institutional investors have recently bought and sold shares of QTRX. Virtu Financial LLC acquired a new position in Quanterix in the 4th quarter valued at about $131,000. Invesco Ltd. grew its stake in shares of Quanterix by 14.7% in the fourth quarter. Invesco Ltd. now owns 113,200 shares of the company's stock worth $720,000 after acquiring an additional 14,508 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Quanterix by 555.1% in the fourth quarter. XTX Topco Ltd now owns 74,093 shares of the company's stock valued at $471,000 after acquiring an additional 62,783 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in Quanterix during the 4th quarter worth $1,079,000. Finally, Quadrature Capital Ltd acquired a new stake in Quanterix in the 4th quarter valued at about $138,000. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.